HRP20080538T3 - Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition - Google Patents

Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Info

Publication number
HRP20080538T3
HRP20080538T3 HR20080538T HRP20080538T HRP20080538T3 HR P20080538 T3 HRP20080538 T3 HR P20080538T3 HR 20080538 T HR20080538 T HR 20080538T HR P20080538 T HRP20080538 T HR P20080538T HR P20080538 T3 HRP20080538 T3 HR P20080538T3
Authority
HR
Croatia
Prior art keywords
alkyl
group
halogen
optionally substituted
combination
Prior art date
Application number
HR20080538T
Other languages
English (en)
Croatian (hr)
Inventor
W. Feenstra Roelof
Stoit Axel
Terpstra Jan-Willem
L. Pras-Raves Maria
C. Mccreary Andrew
J. Van Vliet Bernard
B. Hesselink Mayke
G. Kruse Cornelis
J.M. Van Scharrenburg Gustaaf
Original Assignee
Solvay Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.
Publication of HRP20080538T3 publication Critical patent/HRP20080538T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20080538T 2004-12-08 2005-12-06 Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition HRP20080538T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08
PCT/EP2005/056505 WO2006061376A1 (en) 2004-12-08 2005-12-06 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
HRP20080538T3 true HRP20080538T3 (en) 2008-12-31

Family

ID=35744728

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20080538T HRP20080538T3 (en) 2004-12-08 2005-12-06 Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
HR20090015T HRP20090015T3 (en) 2004-12-08 2005-12-06 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20090015T HRP20090015T3 (en) 2004-12-08 2005-12-06 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Country Status (18)

Country Link
EP (4) EP1827427B1 (enExample)
JP (4) JP2008537725A (enExample)
KR (4) KR20070085916A (enExample)
AT (2) ATE413173T1 (enExample)
AU (4) AU2005313391A1 (enExample)
BR (1) BRPI0518613A2 (enExample)
CA (4) CA2587202A1 (enExample)
DE (2) DE602005010902D1 (enExample)
DK (2) DK1824479T3 (enExample)
ES (2) ES2317335T3 (enExample)
HR (2) HRP20080538T3 (enExample)
IL (4) IL183063A0 (enExample)
NO (4) NO20072969L (enExample)
PL (2) PL1824479T3 (enExample)
PT (2) PT1824479E (enExample)
RU (4) RU2007125661A (enExample)
SI (2) SI1824479T1 (enExample)
WO (4) WO2006061377A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0706778A2 (pt) * 2006-01-30 2011-04-05 Speedel Experimenta Ag processos para a preparação estéreo-seletiva de álcoois a partir de compostos alfa, beta-insaturados
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
CA2671554A1 (en) * 2007-01-10 2008-07-17 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
JP5431306B2 (ja) * 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしてのチア（ジア）ゾール
WO2008128995A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2148872A1 (en) * 2007-04-23 2010-02-03 Janssen Pharmaceutica, N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
CA2327359A1 (en) * 1998-04-08 1999-10-14 Wyeth N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
WO1999067237A1 (en) * 1998-06-19 1999-12-29 H. Lundbeck A/S 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
JP4919565B2 (ja) * 1999-08-23 2012-04-18 アボツト・ヘルスケア・プロダクツ・ベー・ブイ 新規なフェニルピペラジン
PL375350A1 (en) * 2002-12-10 2005-11-28 Merck Patent Gmbh Indol derivatives and their use as 5-ht ligands

Also Published As

Publication number Publication date
AU2005313391A1 (en) 2006-06-15
IL183062A0 (en) 2007-09-20
JP2008537725A (ja) 2008-09-25
NO20072969L (no) 2007-08-31
KR20070085959A (ko) 2007-08-27
CA2587381A1 (en) 2006-06-15
SI1824479T1 (sl) 2009-04-30
WO2006061378A1 (en) 2006-06-15
JP2008523029A (ja) 2008-07-03
WO2006061377A1 (en) 2006-06-15
RU2007125660A (ru) 2009-01-20
EP1827426A1 (en) 2007-09-05
PL1827427T3 (pl) 2009-01-30
HRP20090015T3 (en) 2009-02-28
KR20070085975A (ko) 2007-08-27
SI1827427T1 (sl) 2008-12-31
EP1824479A1 (en) 2007-08-29
CA2587357A1 (en) 2006-06-15
PT1827427E (pt) 2008-11-03
ATE401883T1 (de) 2008-08-15
CA2587559A1 (en) 2006-06-15
DK1824479T3 (da) 2009-03-09
DE602005008471D1 (de) 2008-09-04
BRPI0518613A2 (pt) 2008-11-25
IL183063A0 (en) 2007-09-20
JP2008523031A (ja) 2008-07-03
AU2005313390A1 (en) 2006-06-15
ES2317335T3 (es) 2009-04-16
EP1824479B1 (en) 2008-11-05
RU2007125661A (ru) 2009-01-20
JP2008523030A (ja) 2008-07-03
KR20070085988A (ko) 2007-08-27
IL183061A0 (en) 2007-09-20
WO2006061379A1 (en) 2006-06-15
NO20072974L (no) 2007-08-23
DE602005010902D1 (de) 2008-12-18
RU2007125659A (ru) 2009-01-20
NO20072977L (no) 2007-09-05
EP1827427A1 (en) 2007-09-05
ES2311245T3 (es) 2009-02-01
IL183064A0 (en) 2007-09-20
AU2005313311A1 (en) 2006-06-15
RU2007125658A (ru) 2009-01-20
PL1824479T3 (pl) 2009-04-30
DK1827427T3 (da) 2008-11-24
CA2587202A1 (en) 2006-06-15
PT1824479E (pt) 2009-01-30
EP1824480A1 (en) 2007-08-29
KR20070085916A (ko) 2007-08-27
AU2005313312A1 (en) 2006-06-15
EP1827427B1 (en) 2008-07-23
ATE413173T1 (de) 2008-11-15
NO20072981L (no) 2007-09-05
WO2006061376A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
HRP20080538T3 (en) Aryloxyethylamine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
NO20074057L (no) 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
TW200634017A (en) Bi-and tricyclic substituted phenyl methanones
MY176115A (en) Method for preparing 5-haloalkyl-4, 5-dihydroisoxazole derivatives
UA100248C2 (en) Heterocyclic compound and pharmaceutical composition thereof
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
AR009811A1 (es) Compuestos herbicidas, proceso para su produccion, proceso para la produccion de intermediarios, compuestos intermediarios para su exclusivo usoen dicho proceso, composicion que tiene actividad herbicida selectiva y proceso para el control selectivo de malas hierbas y gramineas en cultivos de planta
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
PA8797301A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
EA200900834A1 (ru) Новый способ получения функционализированных бензоциклобутенов и их применение в синтезе ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
ATE383385T1 (de) 2-flouroalkyl-thieno(3,4-b)thiophen derivate und daraus hergestellte polymere
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
EA201101298A1 (ru) Аддитивные соли трометамина с производными азабифениламинобензойной кислоты в качестве ингибиторов dhodh
UA88329C2 (en) Dna-pk inhibitors
JOP20190239A1 (ar) مركبات مثبطة لـ vmat2 وتركيبات منها
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
EA200601358A1 (ru) Новые ингибиторы химазы
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
NO20043850L (no) 10-(3-Cyklopropylaminometyl-1-pyrrolidinyl) pyridobenzo ksazinkarboksylsyrerederivater effektive mot medikament-resistente bakterier
CO5690581A2 (es) Derivados de cicloalquilo 1,3-sustituidos que tienen grupos acidicos principalmente grupos heterociclicos; procedimientos para su preparacion y su uso como medicamentos
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
HRP20110780T1 (hr) Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6